NA
PTGX icon

NewEdge Advisors’s Protagonist Therapeutics PTGX Stock Holding History

NewEdge Advisors’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-3,230
Closed -$89.2K – 3616
2023
Q2 		$89.2K Buy
+3,230
New +$80.8K ﹤0.01% 1885

Other funds holding PTGX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

NewEdge Advisors's PTGX Position: Q3 2023 in Review

NewEdge Advisors sold out of Protagonist Therapeutics (PTGX) in Q3 2023, closing a stake of 3,230 shares — an estimated $89.2K sold.

NewEdge Advisors first reported a position in PTGX in Q2 2023 and held it in 1 quarter. The position peaked at $89.2K in Q2 2023. 144 funds tracked by Wall St. Rank hold PTGX as of Q3 2023.

  • NewEdge Advisors reported no remaining Protagonist Therapeutics position as of Q3 2023 after selling out during the quarter.
  • NewEdge Advisors sold 3,230 Protagonist Therapeutics shares in Q3 2023, an estimated $89.2K.
  • NewEdge Advisors first reported a position in Protagonist Therapeutics in Q2 2023 and held it in 1 quarter.
  • NewEdge Advisors's Protagonist Therapeutics position peaked at $89.2K in Q2 2023.
  • 144 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q3 2023.

Based on NewEdge Advisors's 13F filing for Q3 2023, filed 14 Nov 2023.